Test of everolimus to reduce transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years
- You have a kidney transplant
- Your biopsy must show microvascular inflammation with only mild chronic scarring
- Your blood tests must NOT show donor-specific antibodies
- Your biopsy must indicate a “missing self” immune marker
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial is testing a stronger combination of four immune-suppressing medicines (including mTOR inhibitors) to help prevent rejection in kidney transplant patients who have a high level of antibodies. It aims to see if this approach works better than standard care for these 'sensitized' patients.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
Hear when a new Kidney Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.